EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 9th, 2019 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Hong Kong
NOW, THEREFORE, in consideration of the foregoing preliminary statements, the mutual agreements and covenants set out herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:
INVESTMENT AGREEMENTInvestment Agreement • August 9th, 2019 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances)
(for the avoidance of doubt, with respect to RMB 1,666,667 of registered capital held by [***] according to the Series A Investment Agreement, [***] shall be regarded as Series A Investor; with respect to RMB 1,175,439 of registered capital held by [***] according to this Agreement, [***] shall be regarded as Series A+ Investor; each party referenced above, a “Party” and collectively, the “Parties”; Series A Investors and Series A+ Investors, each the “Investor” and collectively the “Investors”).
